Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction

by Kathy Jones on  November 14, 2011 at 8:31 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new study published in the New England Journal of Medicine reveals that the oral anticoagulant rivaroxaban improves survival rates after a myocardial infarction when given in combination standard antiplatelet therapy
 Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction
Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction

More than 15,500 patients took part in the ATLAS-ACS 2-TIMI 51 trial and were given either a placebo or 2.5 mg or 5 mg of rivaroxaban for over a period of 13 months.

The number of cardiovascular deaths, MI, or strokes was lower in the group taking rivaroxaban at 8.9 percent compared to 10.7 percent in the placebo group.

Lead researcher Michael Gibson of Harvard, who presented the findings at the American Heart Association meeting, said that a number of deaths can be prevented if antiplatelet therapy is used to treat the patients. "One death would be prevented if 56 patients on antiplatelet therapies were treated for two years with rivaroxaban 2.5 mg twice daily", he said.


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Reiki and Pranic Healing Cardiac Markers 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive